Table 1.
Treatment-naive, number or median (% or range) | On ibrutinib, number or median (% or range) | On acalabrutinib, number or median (% or range) | Progressing, number or median (% or range) | |
---|---|---|---|---|
Age | 59 (48-77) | 67 (53-78) | 61 (50-74) | 64 (39-76) |
Sex | ||||
Female | 10 (50%) | 6 (50%) | 6 (40%) | 0 (0%) |
Male | 10 (50%) | 6 (50%) | 9 (60%) | 10 (100%) |
Prior therapy | ||||
No | 20 (100%) | 6 (60%) | 5 (33%) | 8 (80%) |
Yes | 0 (0%) | 4 (40%) | 10 (67%) | 2 (20%) |
IGHV | ||||
Mutated | 8 (40%) | 5 (42%) | 5 (33%) | 0 (0%) |
Unmutated | 10 (50%) | 5 (42%) | 10 (67%) | 10 (100%) |
Missing | 2 (10%) | 2 (16%) | 0 (0%) | 0 (0%) |
FISH | ||||
del 17p | 2 (10%) | 4 (33%) | 1 (7%) | 6 (60%) |
Absolute lymphocyte count | 110 (10-328) | 37 (5-317) | 31 (4-146) | 12 (6-31) |
T-cell–to–CLL cell ratio | 0.03 (0.01-0.08) | 0.5 (0.01-0.40) | 0.1 (0.01-0.56) | 0.40 (0.08-0.69) |
Time on BTKi therapy (mo) | - | 9 (5.5-57) | 6 (5.2-48) | 50 (15-72) |
All characteristics given apply to the time of sample collection for the study.
Patients treated with ibrutinib (n = 19) or acalabrutinib (n = 18) had completed at least 6 cycles, and 10 (37%) had completed at least 12 cycles.
Among patients with disease progression, 7 (70%) were treated with ibrutinib and 3 (30%) with acalabrutinib.
FISH, florescence in situ hybrization; IGHV, immunoglobulin heavy-chain variable region mutational status.